Iksuda Therapeutics
https://iksuda.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Iksuda Therapeutics
Korea 2024 Outlook: Continued Focus On Drug Delivery Technologies
In a tough R&D environment, delivery technology-based new drug development activities by Korean firms are poised to remain robust in 2024.
Korea 2023 Review: R&D Potential Shines Through Despite Challenges
Despite some disappointments, the South Korean pharma industry showed mostly resilient R&D activity in 2023 amid robust efforts to secure technologies and assets in new modalities such as ADCs and TPD to better compete with global players.
Biosimilars And Beyond: Celltrion Aiming For $9bn Post Merger
After years of talks, Korea's Celltrion Group is finally moving ahead with the merger of three key affiliates aimed at improving cost competitiveness and securing investment resources, as well as simplifying transaction structures and improving governance.
Biosimilars And Beyond: Celltrion Aiming For $9bn Post Merger
After years of talks, Korea's Celltrion Group is finally moving ahead with the merger of three key affiliates aimed at improving cost competitiveness and securing investment resources, as well as simplifying transaction structures and improving governance.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Other Names / Subsidiaries
-
- Glythera Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice